Catalog No.
Product Name
Application
Product Information
Citations
-
FKBP Ligand
SLF TFA is a synthetic ligand specifically targeting FK506-binding proteins (FKBPs), exhibiting an affinity of 3.1 μM for FKBP51 and an IC50 value of 2.6 μM for FKBP12. This compound is pivotal in research applications involving the development of PROTACs (proteolysis-targeting chimeras), which facilitate targeted protein degradation. Its selective interaction with FKBPs underscores its potential utility in studying protein regulation and cellular processes. -
Target Protein Ligand-Linker Conjugate
FKBP12 Ligand-Linker Conjugate 1 is designed to bind the FKBP12 protein, serving as a critical component in targeted protein degradation applications. This conjugate facilitates the synthesis of PROTAC degrader MC-25B, enabling researchers to study the modulation of protein levels within cellular systems. Its utility in chemical biology makes it a valuable tool for investigating protein interaction dynamics and therapeutic development. -
Immunosuppressive Modulator
ILS-920 is an immunosuppressive modulator and a nonimmunosuppressive analog of Rapamycin, designed to exhibit reduced immunosuppressive effects while retaining neuroprotective properties. It selectively binds to FKBP52 and the β1-subunit of L-type voltage-gated calcium channels (VGCC), demonstrating a remarkable 200-fold selectivity for FKBP52 over FKBP12. This compound is of particular interest in research areas focusing on neuroprotection and the modulation of calcium signaling pathways. -
FKBP12 Ligand
FKBP12 ligand-2 is a high-affinity ligand that selectively targets FKBP12. This compound enhances the binding of heterobifunctional molecules to BRD4, facilitating the formation of a ternary complex of FKBP12, ligand, and BRD4 through the "CellTrap" effect. The resulting complex exhibits inhibitory activity against BRD4, leading to the downregulation of BRD4 target genes such as MYC and promoting cancer cell apoptosis. FKBP12 ligand-2 is suitable for research applications focused on cancer mechanisms influenced by intracellular protein levels. -
FKBP51 F67V Antagonist Ligand
FKBP51F67V-selective antagonist Ligand2 is a potent ligand specifically targeting the FKBP51 F67V variant. It effectively reverses the anxiogenic phenotype induced by the overexpression of FKBP51 F67V in the amygdala, thereby highlighting its potential in anxiety research. This compound selectively binds to FKBP51 F67V without interacting with wild-type FKBP51 or FKBP52, making it a valuable tool for studying the specific roles of FKBP51 F67V in neurobiology and related disorders. -
PROTAC FKBP12 Degrader
10-SLF is a PROTAC FKBP12 degrader that facilitates the formation of a ternary complex between FKBP12 and the mutant E3 ligase FBXW7-R465C. This compound promotes the FBXW7-R465C-mediated proteasomal degradation of FKBP12, selectively lowering FKBP12 levels in cells harboring the FBXW7-R465C mutation. 10-SLF is valuable for studying protein degradation pathways and the role of FKBP12 in various biological contexts. -
FKBP12 Ligand
FKBP12 ligand-3 is a high-affinity ligand that selectively targets FKBP12. By facilitating the binding of heterobifunctional molecules to BRD4, it enhances intracellular drug enrichment through the "CellTrap" effect, leading to the formation of a ternary complex of FKBP12-ligand-BRD4. This complex exhibits inhibitory effects on BRD4, resulting in the downregulation of target genes such as MYC and promoting tumor cell apoptosis. FKBP12 ligand-3 is valuable for research focused on cancer therapeutics, particularly in studies that exploit variations in intracellular presenter protein levels. -
FKBP12 Ligand
FKBP12 Ligand-1 is a specific ligand designed to target FKBP12, facilitating the selective recruitment of proteins for ubiquitin-mediated degradation. This compound is primarily utilized in research applications involving proteolysis-targeting chimera (PROTAC) technology, particularly with MC-25B. FKBP12 Ligand-1 serves as a vital tool for studying protein degradation pathways and examining the functional dynamics of cellular targets.
-
Nucleoprotein PROTAC Degrader
KB03-SLF is an electrophilic PROTAC degrader targeting DCAF16 to facilitate the degradation of the nuclear protein FKBP12. This compound serves as a valuable tool in cancer research, enabling the investigation of protein homeostasis and degradation pathways. KB03-SLF’s unique structure incorporates specific ligands that enhance its efficacy as a degradative agent, making it a significant asset for studies focused on targeted protein elimination. -
Fv Domain-Selective Lligand
AP21998 is a selective ligand for the Fv domain of mutant FKBP, primarily targeting FKBPv. This compound effectively disrupts FKBP-mediated oligomerization, leading to the inhibition of proliferation in transformed myeloid progenitors while promoting their terminal myeloid differentiation. Additionally, AP21998 facilitates the resolution of aggregates in CAD-hM1 receptor fusion proteins, enabling their transit from the endoplasmic reticulum to the plasma membrane. Its unique properties make it valuable for research in cancer biology and related fields. -
FKBP12 PROTAC Degrader
RAFKBP12 is a PROTAC degrader that specifically targets FKBP12, utilizing the CAP-TAC strategy to facilitate proteasome-dependent degradation. This compound operates independently of E3 ubiquitin ligases and protein ubiquitination, demonstrating its innovative mechanism of action. RAFKBP12 serves as a valuable tool for research in protein degradation pathways and therapeutic applications related to FKBP12 modulation. -
Immunosuppressant
L 683519 is an immunosuppressant that primarily targets FK-506 binding protein (FKBP). It functions by inhibiting the activity of FKBP, which plays a crucial role in regulating immune responses. This compound is useful for studying immunosuppressive mechanisms and can provide insights into therapies related to organ transplantation and autoimmune diseases. -
FKBP12 Ligand
MP-010 is a potent FKBP12 ligand that modulates cytosolic calcium levels by stabilizing ryanodine receptor (RyR) channel activity. This compound has been shown to enhance functional outcomes in SOD1G93A amyotrophic lateral sclerosis (ALS) mouse models, evidenced by improved motor coordination, enhanced integrity of neuromuscular junctions, and increased survival of spinal motor neurons. MP-010 serves as a valuable tool in the investigation of neurological disorders and the underlying mechanisms of ALS. -
FKBP35 Inhibitor
D44 is a selective inhibitor of FKBP35, targeting the PPIase activity essential for Plasmodium survival. With IC50 values of 132 nM for Plasmodium falciparum and 125 nM for Plasmodium vivax, D44 demonstrates significant antiplasmodium activity. This compound is valuable for research applications focused on malaria and other infectious diseases, providing insights into potential therapeutic approaches. -
FKBP52 Targeting Agents
MJC13 is an FKBP52-targeted agent that exhibits anti-tumor activity, making it a valuable tool in prostate cancer research. By selectively interacting with FKBP52, MJC13 may influence cancer cell proliferation and survival. This reagent is suitable for studies investigating the role of FKBP52 in cancer biology and therapeutic approaches targeting this mechanism. -
FKBP (F36V) Ligand
Shield-2 is a potent stabilizing ligand that specifically targets the FKBP (F36V) protein, exhibiting a dissociation constant of 29 nM. This compound effectively binds to FKBP mutants, which destabilize protein domains and subsequently prevents their degradation. Shield-2 offers a valuable tool for researchers studying intracellular protein regulation and the modulation of protein levels within cellular environments. -
Cytolysin
TAM470 is a novel cytolysin that functions by inhibiting tubulin polymerization and facilitating microtubule depolymerization. This compound serves as a valuable payload molecule in the synthesis of OMTX705, a groundbreaking antibody-drug conjugate (ADC) targeting fibroblast activation protein (FAP) and demonstrating significant antitumor activity. TAM470 is of interest for research into cancer therapeutics and the development of targeted delivery systems. -
STING Agonist
STING agonist-18 diTFA is a potent STING (Stimulator of Interferon Genes) agonist that activates the STING pathway, leading to enhanced immune responses. This compound is useful for the synthesis of antibody-drug conjugates (ADCs), enabling targeted delivery of therapeutics. Its potential applications in cancer immunotherapy and other immune-mediated therapies make it a valuable reagent for research in drug development and immunological studies. -
STING Agonist
STING agonist-49 is a powerful stimulator of the STING (Stimulator of Interferon Genes) pathway, engaging the immune response through Type I interferon production. This compound demonstrates potent biological activity in modulating immune responses, making it a valuable tool in lung cancer research. STING agonist-49 can also serve as an effective payload in antibody-drug conjugates (ADCs), enhancing targeted therapeutic approaches in various malignancies. -
WNT7A Inhibitor/Photosensitizer
WNT7A-IN-1 is a WNT7A inhibitor that disrupts the interaction between WNT7A and its receptor FZD5, leading to the upregulation of MHC-I expression. This compound enhances the expression of MHC-I and phosphorylated p65 while decreasing the levels of active β-catenin. Additionally, WNT7A-IN-1 serves as a photosensitizer in the green spectral region, making it valuable for research in cancer immunotherapy and photodynamic therapy applications. -
COX-2 Inhibitor
APHS is a selective and covalent inhibitor of cyclooxygenase-2 (COX-2) that exerts neuroprotective effects. By acetylating serine 516 in the active site of COX-2, APHS effectively inhibits prostaglandin production, which is often upregulated in colorectal cancer. In addition to its role as a COX-2 inhibitor, APHS also co-inhibits the WNT signaling pathway, contributing to its anti-tumor mechanisms. This compound is valuable for research into cancer biology and neuroprotection. -
5-LO/COX-2/DPP-4 Inhibitor
Timosaponin A1 is a natural steroidal saponin that acts as an inhibitor of 5-lipoxygenase (5-LO), cyclooxygenase-2 (COX-2), and dipeptidyl peptidase 4 (DPP-4), with IC50 values of 3.29 µM, 36.43 µM, and 33.25 µM, respectively. This compound exhibits anti-inflammatory properties and is relevant for research on conditions such as asthma and diabetes. Its inhibitory effects on key enzymes involved in inflammatory pathways make it a valuable tool for exploring therapeutic strategies in related biological studies. -
Arginase Inhibitor
nor-NOHA monoacetate is a selective and reversible inhibitor of arginase. It induces apoptosis in cells expressing arginase 2 under hypoxic conditions and demonstrates anti-leukemic activity. This compound is valuable for investigating endothelial dysfunction, immunosuppression, and metabolic processes in various biological contexts. -
Arginase Inhibitor
ABH hydrochloride is a potent arginase inhibitor with a Ki value of 8.5 nM. This compound enhances nitric oxide production and downregulates inflammatory mediators, including ICAM-1, VCAM-1, and MCP-1. ABH hydrochloride is utilized in research focused on erectile dysfunction, lung protection, wound healing, blood pressure regulation, and vascular fibrosis. Its dual role in promoting vasodilation and reducing inflammation makes it a valuable reagent for studying cardiovascular and inflammatory diseases. -
Arginase Inhibitor
OATD-02 is a competitive, reversible, noncovalent inhibitor that targets arginase 1 and 2. It exhibits slow offset kinetics with IC50 values of 20 nM for human arginase 1, 39 nM for human arginase 2, 39 nM for mouse arginase 1, and 28 nM for rat arginase 1. OATD-02 effectively disrupts tumor immunosuppression mediated by arginases, making it a valuable tool for research in melanoma and other cancer immunotherapy studies. -
Arginase Inhibitor
ARG1-IN-1 is a potent arginase inhibitor with an IC50 value of 29 nM. This compound effectively inhibits serum arginase activity, leading to increased levels of arginine in various mouse tumor models. ARG1-IN-1 is particularly useful for research applications focused on tumor biology and arginine metabolism in cancer. -
Arginase Inhibitor
NED-3238 is a potent inhibitor of arginase I and II, exhibiting IC50 values of 1.3 nM and 8.1 nM, respectively. This compound is valuable in research focused on metabolic regulation and immune modulation, facilitating studies related to cancer, cardiovascular diseases, and inflammation. Its high specificity and potency make it a suitable tool for investigating arginine metabolism and its implications in various biological processes. -
Arginase Inhibitor
(-)-3-O-Acetylcatechin is an arginase inhibitor that demonstrates significant activity against Leishmania amazonensis, with an IC50 value of 3.7 μM. This compound serves as a valuable tool for investigating leishmaniasis and studying arginase-related metabolic pathways in parasitic infections. Its application in biochemical research may contribute to the development of therapeutic strategies for managing leishmaniasis. -
Arginase Inhibitor
BEC is a competitive inhibitor of the binuclear manganese metalloenzyme arginase, functioning as an arginine analogue with slow-binding characteristics. This compound promotes the increased availability of arginine for nitric oxide synthase, thereby facilitating nitric oxide-dependent smooth muscle relaxation in the corpus cavernosum. As a result, BEC is significant in studies related to penile erection and vascular health. -
Arginase Inhibitor
NG-Hydroxy-L-arginine acetate is a selective arginase inhibitor that participates in modulating the nitric oxide pathway. By interfering with the conversion of arginine to citrulline, it facilitates increased nitric oxide production via nitric oxide synthase. This compound is valuable in research related to cardiovascular health, neurobiology, and inflammation, where nitric oxide signaling plays a critical role. -
Antibiotic Agent
Cloxacillin sodium is a β-lactam antibiotic and a potent β-lactamase inhibitor with an IC50 of 0.04 µM. It exhibits significant antibacterial activity, particularly against Staphylococcus aureus, and can effectively attenuate the S. aureus-induced inflammatory response by inhibiting the activation of MAPK, NF-κB, and NLRP3-related proteins. This compound is relevant for research in antimicrobial resistance and inflammation pathways. -
Anti-inflammatory/Antimicrobial Agent
Myricetin 3-O-glucoside, a flavonol derived from Tibouchina paratropica and Hakmeitau beans, primarily functions as an anti-inflammatory and antimicrobial agent. This compound demonstrates notable anti-Leishmanial activity, making it a valuable tool for studying inflammatory pathways and infectious diseases in research. Its diverse biological properties contribute to investigations in pharmacology and natural product chemistry. -
Antiviral/Anti-inflammatory Agent
Retusin, also known as Quercetin-3,3',4',7-tetramethylether, is a natural compound derived from the leaves of Talinum triangulare. It exhibits antiviral and anti-inflammatory properties, making it a valuable reagent for research into viral infections and inflammatory conditions. This compound’s dual activity supports investigations aimed at elucidating the mechanisms underlying viral pathogenesis and the inflammatory response. -
Anti-inflammatory Agent
Morelloflavone is an anti-inflammatory agent that exhibits significant antioxidative and antiviral properties. This compound has been shown to modulate inflammatory pathways, making it valuable for research into inflammatory diseases and potential therapeutic applications. Its diverse biological activities make Morelloflavone a relevant candidate for studies focused on oxidative stress and inflammation-related mechanisms. -
COX-2 Inhibitor
Thymohydroquinone is a selective inhibitor of cyclooxygenase-2 (COX-2) with noted anti-SARS-CoV-2 activity. It exhibits cytotoxic properties, antiproliferative effects, and the ability to suppress tumor growth in various cancer models. This compound is applicable in research focused on squamous cell carcinoma, fibrosarcoma, and the pathogenesis and treatment of COVID-19 caused by SARS-CoV-2. -
HPV Epitope Peptides Fragment
Human Papillomavirus (HPV) E7 protein (49-57) is a fragment of the E7 protein, specifically the epitope spanning amino acid residues 49 to 57, which is restricted by the H-2d MHC class I molecule. This peptide is vital for studying HPV-induced tumorigenesis and immune response mechanisms. It is commonly utilized in research applications focusing on HPV vaccination, T cell recognition, and the understanding of viral oncogenesis. -
Antiviral/Anti-Inflammatory Glycoprotein
Lactoferrin from Bovine Milk is a multifunctional iron-binding glycoprotein that exhibits antiviral and anti-inflammatory properties. Released by neutrophils, it plays a crucial role in inhibiting microbial and viral adhesion, as well as entry into host cells. This compound is also known to prevent cell adhesion and growth, contributing to its potential anti-cancer and immunomodulatory effects. Lactoferrin is widely applied in research focused on immune response modulation and pathogen resistance. -
Anti-inflammatory Agent
Astin C is a cyclopeptide derived from Aster tataricus that acts as an anti-inflammatory agent. It specifically inhibits the cGAS-STING signaling pathway, preventing the recruitment of IRF3 to the STING signalosome, thereby modulating the innate inflammatory response. Astin C is valuable for research into autoimmune diseases and cancer, making it a key reagent for studying inflammation-related mechanisms. -
iNOS Inhibitor
S-Methylisothiourea sulfate serves as a potent, selective, and competitive inhibitor of inducible nitric oxide synthase (iNOS). This compound has demonstrated significant biological activity in reducing nitric oxide production and exhibits protective effects in rodent models of septic shock. Its role in modulating iNOS activity makes it a valuable reagent for research focused on inflammation and immune response mechanisms. -
Anti-inflammatory/Antiinfection Agent
Forsyshiyanine A is a triterpenoid alkaloid known for its anti-inflammatory and antiviral properties. It effectively inhibits the release of β-glucuronidase from rat polymorphonuclear leukocytes, thereby demonstrating notable anti-inflammatory activity. Forsyshiyanine A also exhibits antiviral efficacy, with an EC50 of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 of 7.3 μM against influenza A virus (H1N1), reducing viral load through disruption of viral replication and entry. This compound is valuable for research in the fields of inflammation and infection. -
Bioactive Peptide
Influenza NP (311-325) is a bioactive peptide derived from the nucleoprotein (NP) of the influenza virus, acting as an MHC class II restricted epitope to stimulate host immune responses. This peptide is known for its ability to induce substantial interferon gamma (IFN-γ) production while avoiding activation of CD8 T cells in murine models. Its unique properties make Influenza NP (311-325) a valuable tool for research in immunology and vaccine development. -
Anti-Inflammatory Agent
Agathisflavone is a flavonoid compound primarily recognized for its anti-inflammatory properties. It exhibits a range of biological activities, including antioxidant, antiviral, antiparasitic, cytotoxic, neuroprotective, and hepatoprotective effects. Research indicates that Agathisflavone may enhance tissue repair processes, particularly in spinal cord injury models in rodents, making it a valuable reagent for studies in inflammation and regenerative medicine. -
Nonimmunosuppressive Cyclophilin Inhibitor
NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor, specifically targeting cyclophilin A with a Kd of 1.2 nM. It exhibits significant anti-HCV activity, with an EC50 of 40 nM. This compound serves as a valuable tool for research into HCV infection and its associated pathways. -
CXCR4 Antagonist
Mavorixafor trihydrochloride is a potent and selective antagonist of the CXCR4 receptor, exhibiting an IC50 of 13 nM in inhibiting CXCR4 125I-SDF binding. This compound has demonstrated significant antiviral activity by inhibiting the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs, with IC50 values of 1 nM and 9 nM, respectively. Mavorixafor trihydrochloride is applicable in research studying WHIM syndrome and various CXCR4-related biological processes. -
CCR7 and CXCR2 Antagonist
Cosalane is a dual antagonist of the chemokine receptors CCR7 (IC50 = 2.43 μM) and CXCR2 (IC50 = 0.66 μM). This compound effectively inhibits HIV replication across a variety of strains, including HIV-1, HIV-2, Rauscher murine leukemia virus, as well as herpes simplex viruses HSV-1 and HSV-2, and human cytomegalovirus. Cosalane disrupts the interaction between gp120 and CD4, inhibiting signaling downstream of CCR7 in response to its ligands CCL19 and CCL21. Research applications include studies on HIV and the potential modulation of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. -
CCR5 Inhibitor
DAPTA is a synthetic peptide that acts as a selective inhibitor of the CCR5 receptor. By blocking CCR5, DAPTA interferes with viral entry into host cells, exhibiting significant anti-HIV activity. This compound is valuable for research in virology and the development of therapeutic strategies against HIV. -
CXCR4 Antagonist
TC14012 is a peptidomimetic antagonist targeting the chemokine receptor CXCR4, exhibiting a high level of selectivity with an IC50 of 19.3 nM. In addition, TC14012 acts as a potent agonist for CXCR7, demonstrating an EC50 of 350 nM in β-arrestin 2 recruitment assays. This compound is utilized in research focused on HIV and cancer therapy, showcasing its potential in modulating chemokine signaling pathways. -
CXCR4 Antagonist
FC131 TFA is a potent CXCR4 antagonist that effectively inhibits the binding of [125I]-SDF-1 to CXCR4, demonstrating an IC50 value of 4.5 nM. This compound exhibits significant anti-HIV activity, making it a valuable tool for research in HIV treatment and other CXCR4-related studies. Its ability to disrupt CXCR4 signaling can be explored in various biological contexts, including cancer metastasis and immune response regulation. -
CXCR4 Antagonist
AMD 3465 is a potent antagonist of the CXCR4 chemokine receptor. It effectively inhibits the binding of both the 12G5 monoclonal antibody and CXCL12AF647 to CXCR4, demonstrating IC50 values of 0.75 nM and 18 nM in SupT1 cells, respectively. Additionally, AMD 3465 significantly impedes the replication of X4-tropic HIV strains, with IC50 values ranging from 1 to 10 nM, while showing no activity against CCR5-using (R5) viruses. This compound is suitable for research applications focusing on HIV treatment and CXCR4-related signaling pathways. -
CCR5 Antagonist
Aplaviroc hydrochloride is a potent CCR5 antagonist targeting the CCR5 co-receptor. It demonstrates biological activity with IC50 values ranging from 0.1 to 0.4 nM against various HIV-1 strains, including HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW. This compound is valuable for research applications focused on HIV entry inhibition and the development of antiviral therapies.
